The company's product pipeline is built on more than 40 years of research into allopregnanolone-related neurological disorders.

Asarina's new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) aims to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to OCD that still lack safe, efficacious pharmaceutical treatments.